Nichole Tucker

Articles

Adjuvant Ipilimumab Shows Early Activity in Advanced Cervical Cancer

February 21st 2020

Immune checkpoint blockade with ipilimumab, combined with radiation therapy, is tolerable and effective in patients with node-positive, stage Ib2 to IV cervical cancer.

Panobinostat Combo Shows Early Promise in Myelofibrosis and Polycythemia Vera

February 21st 2020

The combination of panobinostat and ruxolitinib demonstrated efficacy and a tolerable safety profile as a treatment for patients with primary myelofibrosis and post-polycythemia vera–related myelofibrosis and post essential thrombocythemia–related myelofibrosis.

Ruxolitinib Combo Elicits Clinical Activity in Polycythemia Vera and Myelofibrosis

January 30th 2020

The combination of ruxolitinib (Jakafi) plus low-dose pegylated interferon-a2 demonstrated an improvement in peripheral blood cell counts bone marrow cellularity and fibrosis, and symptom burden with acceptable toxicity in patients with polycythemia vera or proliferative myelofibrosis.

Bekaii-Saab Sheds Light on Furthering Biomarker-Driven Treatment in GI Cancers

January 26th 2020

Tanios S. Bekaii-Saab, MD, examines the effectiveness of umbrella trials and their importance in aiding precision medicine in gastrointestinal oncology.

Kopetz Highlights Improved QoL, Efficacy With Encorafenib Regimens in BRAF+ mCRC

January 25th 2020

Scott Kopetz, MD, PhD, FACP, sheds light on encorafenib triplet and doublet options for patients with BRAF V600E–mutant metastatic colorectal cancer and other novel regimens under investigation.

Nivolumab Triplet Elicits Clinically Meaningful Responses in Advanced HCC

January 25th 2020

The triplet regimen of nivolumab (Opdivo), ipilimumab (Yervoy), and cabozantinib (Cabometyx) achieved clinically meaningful responses in patients with advanced hepatocellular carcinoma who were either sorafenib (Nexavar)-naïve, or resistant to or intolerant of sorafenib.

Cirmtuzumab/Ibrutinib Study Expands to Include Patients With MCL

November 8th 2019

The phase I/II CIRLL study, which is evaluating the combination of the monoclonal antibody cirmtuzumab (UC-961) plus ibrutinib has opened an expansion cohort to include patients with mantle cell lymphoma.

Expert Shares Insight on Precision Medicine Efforts in MCL

November 7th 2019

Jia Ruan, MD, PhD, hematologist/oncologist, Weil Cornell Medicine, examined the evolving treatment landscape for mantle cell lymphoma, with an emphasis on BTK inhibitors.

BTK Combos Potentially Poised to Be New Standard MCL Treatment

October 9th 2019

Simon Rule, MD, discusses the standard of care for MCL treatment and future regimens that could transform clinical practice.

Larotrectinib Is Highly Active in Patients With NTRK Fusion+ NSCLC

September 10th 2019

Anna F. Farago, MD, PhD, assistant professor of medicine, Harvard Medical School, discusses the updated activity of larotrectinib in NTRK fusion–positive lung cancer.

Expert Discusses Novel Agents in Development Targeting EGFR, HER2+ NSCLC

September 9th 2019

Pasi A. Jänne, MD, PhD, discusses 3 studies of novel agents for targeting EGFR-mutant and HER2-positive lung cancers and the next steps in getting the research to cancer clinics.

Expert Explains USPSTF Update of BRCA Screening Guidelines

August 29th 2019

Carol Mangione, MD, MSPH, shares insight on the specifics of the recommendations related to BRCA-mutation testing and how the USPSTF hopes these suggestions will impact patient outcomes.

Therapeutic Challenges Continue to Emerge in Myelofibrosis

August 28th 2019

James K. McCloskey II, MD, discussed current treatment options for patients with myelofibrosis as well as further options in development in clinical trials.

Regorafenib/Nivolumab Combo Elicits Responses in CRC and Gastric Cancer

August 21st 2019

Shota Fukuoka, MD, PhD, discusses the results of the study evaluating regorafenib and nivolumab in patients with previously treated gastric and colorectal cancers.

Mantle Cell Lymphoma Options Expand, With CAR-T on the Horizon

August 8th 2019

Kieron Dunleavy, MD, discusses the current treatment paradigm in mantle call lymphoma and the emerging potential for CAR T-cell therapy.

Frontline Mantle Cell Lymphoma Treatment Must Involve Personalized Approach

August 7th 2019

Peter Martin, MD, discusses the need for a personalized therapeutic approach in frontline MCL treatment.

Lisocabtagene Maraleucel Elicits Undetectable MRD in Relapsed/Refractory CLL

August 6th 2019

Tanya Siddiqi, MD, explains how novel agents are improving the treatment landscape for chronic lymphocytic leukemia, citing examples from the TRANSCEND CLL 004 trial.

Targeted Agents Transforming AML Paradigm

July 24th 2019

Elias Jabbour, MD, highlights the evolving armamentarium and next steps in the treatment paradigm for acute myeloid leukemia.

Zanubrutinib Continues to Show Encouraging Activity in Relapsed/Refractory MCL

July 19th 2019

Yuqin Song, MD, PhD, discusses the clinical activity with zanubrutinib in patients with relapsed/refractory mantle cell lymphoma.

Targeting Acquired Resistance Leads EGFR+ NSCLC Research Efforts

July 9th 2019

Heather Wakelee, MD, discusses the rationale and findings for two combination regimens in EGFR-mutant non-small cell lung cancer, as well as the implications for our understanding of mechanisms of resistance.